N. Bertoldi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
N. Bertoldi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Annamaria Cattelan
Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy
1 shared publication - Antonella Viola
Department of Biomedical Sciences, University of Padova, Padova, Italy
1 shared publication - Aurora Savino
Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
1 shared publication - Barbara Molon
Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
1 shared publication - C. Putaggio
Infectious Disease Unit, Padova University Hospital
1 shared publication - Carlo Emanuele Villa
Human Technopole, Milan, Italy
1 shared publication
Latest Publications
- Open Access
RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity
The spread of SARS-CoV-2 has fueled the COVID-19 pandemic with its enduring medical and socioeconomic challenges due to subsequent waves and long-term consequences of great concern. Here we charted the molecular basis of COVID-19 pathogenesis, by analysing patients’ immune response at single-cell resolution across disease course and severity. This approach uncovered cell subpopulation-specific dysregulation in COVID-19 across disease course and severity and identified a severity-associated activation of the receptor for advanced glycation endproduct (RAGE) pathway in monocytes. In vitro experiments confirmed that monocytes bind the SARS-CoV-2 S1-RBD via RAGE and that RAGE-Spike interactions drive monocyte infection. Our results demonstrate that RAGE is a novel functional receptor of SARS-CoV-2 contributing to COVID-19 severity. One-Sentence Summary: Monocyte SARS-CoV-2 infection via the receptor for advanced glycation endproduct triggers severe COVID-19.
Open AccessRAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity
The spread of SARS-CoV-2 has fueled the COVID-19 pandemic with its enduring medical and socioeconomic challenges due to subsequent waves and long-term consequences of great concern. Here we charted the molecular basis of COVID-19 pathogenesis, by analysing patients’ immune response at single-cell resolution across disease course and severity. This approach uncovered cell subpopulation-specific dysregulation in COVID-19 across disease course and severity and identified a severity-associated activation of the receptor for advanced glycation endproduct (RAGE) pathway in monocytes. In vitro experiments confirmed that monocytes bind the SARS-CoV-2 S1-RBD via RAGE and that RAGE-Spike interactions drive monocyte infection. Our results demonstrate that RAGE is a novel functional receptor of SARS-CoV-2 contributing to COVID-19 severity. One-Sentence Summary: Monocyte SARS-CoV-2 infection via the receptor for advanced glycation endproduct triggers severe COVID-19.